Vivoryon Therapeutics N.V. (VVY.AS)

EUR 1.97

(0.71%)

Total Debt Summary of Vivoryon Therapeutics N.V.

  • Vivoryon Therapeutics N.V.'s latest annual total debt in 2023 was 38 Thousand EUR , down -71.21% from previous year.
  • Vivoryon Therapeutics N.V.'s latest quarterly total debt in 2024 Q2 was 10 Thousand EUR , down 0.0% from previous quarter.
  • Vivoryon Therapeutics N.V. reported annual total debt of 132 Thousand EUR in 2022, down -41.07% from previous year.
  • Vivoryon Therapeutics N.V. reported annual total debt of 224 Thousand EUR in 2021, down -28.66% from previous year.
  • Vivoryon Therapeutics N.V. reported quarterly total debt of 38 Thousand EUR for 2023 FY, down -71.21% from previous quarter.
  • Vivoryon Therapeutics N.V. reported quarterly total debt of 85 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Total Debt Chart of Vivoryon Therapeutics N.V. (2023 - 2010)

Historical Annual Total Debt of Vivoryon Therapeutics N.V. (2023 - 2010)

Year Total Debt Total Debt Growth
2023 38 Thousand EUR -71.21%
2022 132 Thousand EUR -41.07%
2021 224 Thousand EUR -28.66%
2020 314 Thousand EUR -22.66%
2019 406 Thousand EUR 0.0%
2018 - EUR 0.0%
2017 - EUR 0.0%
2016 - EUR 0.0%
2015 - EUR 0.0%
2014 - EUR -100.0%
2013 5.34 Million EUR 0.0%
2012 - EUR 0.0%
2011 - EUR 0.0%
2010 - EUR 0.0%

Peer Total Debt Comparison of Vivoryon Therapeutics N.V.

Name Total Debt Total Debt Difference
ABIONYX Pharma SA 3.39 Million EUR 98.879%
ABIVAX Société Anonyme 55.46 Million EUR 99.931%
Adocia SA 13.08 Million EUR 99.71%
Aelis Farma SA 4.03 Million EUR 99.059%
Biophytis S.A. 8.27 Million EUR 99.541%
Advicenne S.A. 17.42 Million EUR 99.782%
genOway Société anonyme 7.23 Million EUR 99.475%
IntegraGen SA 1.12 Million EUR 96.621%
Medesis Pharma S.A. 1.2 Million EUR 96.833%
Neovacs S.A. 650 Thousand EUR 94.154%
NFL Biosciences SA 62.17 Thousand EUR 38.881%
Plant Advanced Technologies SA 4.35 Million EUR 99.128%
Quantum Genomics Société Anonyme 2.71 Million EUR 98.601%
Sensorion SA 2.86 Million EUR 98.675%
Theranexus Société Anonyme 3.64 Million EUR 98.957%
TME Pharma N.V. 1.16 Million EUR 96.741%
Valbiotis SA 6.87 Million EUR 99.448%
TheraVet SA 1.15 Million EUR 96.724%
Valerio Therapeutics Société anonyme 8.99 Million EUR 99.578%
argenx SE 18.1 Million EUR 99.79%
BioSenic S.A. 28.16 Million EUR 99.865%
Celyad Oncology SA 902 Thousand EUR 95.787%
DBV Technologies S.A. 13.01 Million USD 99.708%
Galapagos NV 9.59 Million EUR 99.604%
Genfit S.A. 70.17 Million EUR 99.946%
GeNeuro SA 7.73 Million EUR 99.509%
Hyloris Pharmaceuticals SA 5.29 Million EUR 99.282%
Innate Pharma S.A. 39.89 Million EUR 99.905%
Inventiva S.A. 37.4 Million EUR 99.898%
MaaT Pharma SA 14.07 Million EUR 99.73%
MedinCell S.A. 58.96 Million EUR 99.936%
Nanobiotix S.A. 50.56 Million EUR 99.925%
Onward Medical N.V. 16.87 Million EUR 99.775%
Oryzon Genomics S.A. 13.68 Million EUR 99.722%
OSE Immunotherapeutics SA 45.8 Million EUR 99.917%
Oxurion NV 12.33 Million EUR 99.692%
Pharming Group N.V. 155.29 Million EUR 99.976%
Poxel S.A. 46.9 Million EUR 99.919%
GenSight Biologics S.A. 18.42 Million EUR 99.794%
Transgene SA 1.25 Million EUR 96.977%
Financière de Tubize SA 79.2 Million EUR 99.952%
UCB SA 3.03 Billion EUR 99.999%
Valneva SE 208.81 Million EUR 99.982%